DURECT Corporation is focused on advancing epigenetic modulation as a therapeutic approach to address serious medical conditions, particularly acute organ injuries and cancers. Their lead product, larsucosterol, is an epigenetic modulator that targets dysregulated DNA methylation, which is often associated with various diseases. Clinical trials, including a Phase 2b study for alcohol-associated hepatitis (AH), have shown promising results, indicating that larsucosterol may significantly reduce mortality rates in patients suffering from this life-threatening liver condition. The company is committed to exploring the potential of larsucosterol not only for AH but also for other serious conditions, including metabolic dysfunction-associated steatohepatitis (MASH).

In addition to their work on larsucosterol, DURECT has developed proprietary drug delivery technologies, including the SABER® and CLOUD™ platforms, which facilitate the creation of long-acting injectable products. These technologies allow for high drug loading, controlled release, and stabilization of various therapeutic agents, enhancing their efficacy and patient compliance. DURECT also markets the POSIMIR® product, an FDA-approved bupivacaine solution for post-surgical pain management, and manufactures ALZET® osmotic pumps for research applications. Through strategic partnerships and collaborations, DURECT aims to expand its innovative therapeutic options and improve patient outcomes in the field of medicine.

United States

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH).

Cancer

Hematologic Diseases

Liver Diseases

Pathological Conditions

DURECT Corporation

Post operative acute pain

<p class="font_7">POSIMIR is the Company's investigational post-operative pain relief depot product that utilizes DURECT's patented SABER® technology. POSIMIR is designed to be administered directly into the surgical site to deliver bupivacaine for up to three days after surgery.</p>

POSIMIR® (bupivacaine extended-release solution)

Alcoholic hepatitis

Liver disease

<p class="font_7">DURECT's lead drug candidate, DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival.</p>

DURECT Corporation

Company Details